| [1] |
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes[J]. J Clin Oncol, 2010,28(20):3271-3277.
|
| [2] |
No authors listed. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group,Clinical Oncological Society of Australia[J]. J Clin Oncol,1986,4(2):186-193.
|
| [3] |
Taylor SG 4th, Gelman RS, Falkson G, et al. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women[J]. Ann Intern Med,1986,104(4):455-461.
|
| [4] |
Chia S, Gradishar W, Mauriac L, et al. Double-blind,randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive,advanced breast cancer: results from EFECT [J]. J Clin Oncol,2008,26(10):1664-1670.
|
| [5] |
Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer:results from the FIRST study[J]. J Clin Oncol,2009,27(27):4530-4535.
|
| [6] |
Howell A, Robertson JF, Quaresma Albano J, et al.Fulvestrant, formerly ICI 182 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment[J]. J Clin Oncol,2002,20(16):3396-3403.
|
| [7] |
Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲtrial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol,2010,28(30):4594-4600.
|
| [8] |
Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an openlabel randomized phase Ⅲstudy of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer[J]. J Clin Oncol,2012,30(16):1919-1925.
|
| [9] |
Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole and fulvestrant in metastatic breast cancer[J]. N Engl J Med,2012,367(5):435-444.
|
| [10] |
Johnston SR, Kilburn LS, Ellis P, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial[J]. Lancet Oncol,2013,14(10):989-998.
|
| [11] |
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J]. N Engl J Med,2012,366(6):520-529.
|
| [12] |
Bachelot T,Bourgier C,Cropet C,et al. Randomized phase Ⅱtrial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study[J]. J Clin Oncol,2012,30(22):2718-2724.
|
| [13] |
Kaufman B, Mackey JR,Clemens MR,et al.Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase ⅢTAnDEM study[J]. J Clin Oncol,2009,27(33):5529-5537.
|
| [14] |
Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer[J]. J Clin Oncol,2009,27(33):5538-5546.
|